Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients
-
Published:2023-03
Issue:3
Volume:41
Page:148.e17-148.e24
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Gerald ThomasORCID,
Margulis Vitaly,
Meng Xiaosong,
Bagrodia Aditya,
Cole Suzanne,
Qin Qian,
Call S. Greg,
Mauer Elizabeth,
Lotan Yair,
Woldu Solomon L.
Reference43 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
2. Bladder cancer stage and mortality: urban vs. rural residency;Deuker;Cancer Causes Control,2021
3. Network NCC. Bladder cancer (version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Published 2022. Accessed June 1, 2022.
4. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
5. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献